A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs DA 1241 (Primary) ; Sitagliptin
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MetaVia; NeuroBo Pharmaceuticals
- 10 Jan 2025 According to a Metavia media release, the company is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241
- 19 Dec 2024 According to a Metavia media release, the company announced release of positive top-line 16-week results from this trial MASH-TAG Conference which is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah.
- 18 Dec 2024 Primary endpoint has not been met (Part1 & Part 2: Change alanine transaminase (ALT) levels) , according to a NeuroBo Pharmaceuticals media release